ClinicalTrials.Veeva

Menu
Houston Research Institute | Houston, TX logo

Houston Research Institute | Houston, TX

Research site
About
Houston Research Institute is dedicated to conducting clinical trials in the areas of Hepatology and Gastroenterology, with a special focus on fatty liver disease. We pride ourselves on conducting high quality research as a complement to the medical care that our volunteers receive from their routine care center.

Site insights

Top conditions

Top treatments

Resmetirom
TERN-501
HU6
Semaglutide
Lanifibranor
Survodutide
TERN-101
Cilofexor
MK-6024-013
Cagrilintide

Data sourced from clinicaltrials.gov

Contact this site

Kira Harris

Verified by this site

Active trials

9 of 10 total trials

A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013)

The purpose of this study is to learn how well efinopegdutide works compared to placebo in people who have non-alcoholic steatohepatitis (NASH). Rese...

Enrolling
Nonalcoholic Fatty Liver Disease
Fatty Liver, Nonalcoholic
Drug: Semaglutide
Drug: Placebo

This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis histological stage F2 or F3

Enrolling
NASH - Nonalcoholic Steatohepatitis
Drug: Placebo
Drug: IVA337

This study will determine the effect of oral 80 mg resmetirom administered once daily on participants with well-compensated non-alcoholic steatohepat...

Enrolling
NASH
Cirrhosis, Liver
Drug: Resmetirom
Drug: Placebo

This is a safety study to evaluate BOS-580 administered subcutaneously with repeated dosing over 12 weeks in Part A or 24 weeks in Part B. Part C is...

Active, not recruiting
Nonalcoholic Steatohepatitis (NASH)
Drug: BOS-580
Drug: Placebo

This study is open to adults who are at least 18 years old and have a body mass index (BMI)bof 27 kg/m2 or more. People can take part if they have ca...

Enrolling
Obesity
Drug: Placebo
Drug: survodutide

The study will look at the effects of NNC0194-0499, cagrilintide and semaglutide, on liver damage and alcohol use in participants with alcoholic live...

Enrolling
Alcohol-related Liver Disease
Drug: Cagrilintide
Drug: NNC0194-0499 placebo

This is a phase 2 randomized, double-blind, placebo-controlled parallel group study of 3 dose levels of HU6 in subjects with nonalcoholic steatohepat...

Enrolling
Fatty Liver
Nonalcoholic Steatohepatitis
Other: Placebo
Drug: HU6

Semaglutide is a medicine studied in patients with NASH. Semaglutide is a well-known medicine, which is already used by doctors to treat type 2 diabe...

Enrolling
Non-alcoholic Steatohepatitis
Drug: Placebo
Drug: Semaglutide

The goals of this clinical study are to learn more about the study drugs, semaglutide (SEMA) with the fixed-dose combination (FDC) of cilofexor/firso...

Active, not recruiting
Nonalcoholic Steatohepatitis
Drug: PTM CILO/FIR
Drug: Cilofexor (CILO)/Firsocostat (FIR)

Trial sponsors

Novo Nordisk logo
Boehringer Ingelheim logo
Boston Scientific logo
Gilead Sciences logo
I
Madrigal Pharmaceuticals logo
Merck Sharp & Dohme (MSD) logo
Rivus Pharmaceuticals logo
T

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems